Comparative Analysis of FDA and EMA Drug Approval Processes
The FDA employs a centralized and flexible approval system with expedited pathways, potentially leading to shorter review timelines.
High impact 28 min
Updated daily from FDA, EMA, ICH and leading publishers
The pharma industry's research library
Curated regulatory guidance, clinical analyses, and market reports. AI-summarized, editor-reviewed, instantly downloadable.
36whitepapers
8publishers
6regions
Dailyupdates
Research Pulse
Aggregated from live regulatory feeds 36 Research reports In library
8 Publishers FDA, EMA, industry
3 Featured Editor picks
8 Gated downloads Lead-gen reports
Quick answer
NovaPharmaNews hosts 36 curated pharmaceutical whitepapers and industry reports from 8 publishers — FDA and EMA regulatory guidance, clinical analyses, manufacturing intelligence, and market research. 3 featured reports are editor-picked this week. Each landing page includes key takeaways, optional PDF download, and links to related drugs, companies, and pipeline data.
Methodology & data sources Publications & analysis Editorial policy
Browse the library
36 results 
GxP Environmental Monitoring Systems: A Guide for Small Biotechs
Essential guide for small biotechs on GxP environmental monitoring systems to ensure compliance and product quality.
High impact 36 min
FDA's April 30, 2026 ODAC Meeting on Camizestrant Review
Camizestrant is under review for the treatment of ESR1m/HR+/HER2- advanced breast cancer (ABC).
High impact 198 min
Data First: Enhancing Drug Development with FAIR-by-Design Standards
FAIR-by-design standardization is a necessary investment for maximizing NAM data utility.
High impact 28 min
Did You Know: Insights from NCPDP's Active Task Groups
NCPDP has 71 active task groups focusing on diverse areas of pharmacy standards.
High impact 74 min
A26 Informational Reports: Insights for Pharma Stakeholders
Total grants and donations received by the AMA in 2025 amounted to $3,666,000, supporting various public health initiatives.
High impact 300 min
🔒 Medicare Risk Arrangement and Use and Outcomes Among Physician Groups
At-risk Medicare Advantage arrangements show higher quality and efficiency compared to fee-for-service models, impacting care delivery for b…
High impact 20 min
🔒 Lilly's Weight-Loss Pill Approved, Sparking Competition with Novo Nordisk
Eli Lilly's daily weight-loss pill received FDA approval, setting the stage for a competitive battle with Novo Nordisk's Wegovy in the $70 b…
High impact 15 min
🔒 Cigna Medical Coverage Policy: Acupuncture
Cigna's updated policy outlines conditions for acupuncture coverage, including migraine and musculoskeletal pain, effective April 2026.
High impact 20 min
🔒 Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only)
This policy outlines medically necessary radiation therapy protocols for conditions like breast cancer and lung cancer, effective April 1, 2…
High impact 11 min
🔒 Patient Mastering as Enterprise Infrastructure
Effective patient mastering is crucial for healthcare organizations to ensure accurate patient journeys and reliable analytics, impacting st…
High impact 8 min
Clinical Appropriateness Guidelines for Imaging of the Chest
This whitepaper outlines the clinical appropriateness guidelines for chest imaging, aimed at improving patient care and standardizing practi…
High impact 5 min
Drug Testing for Substance Use and Pain Management
This medical policy outlines guidelines for urine drug testing in pain management and substance use treatment.
High impact 5 min
FDA Draft Guidance on AI in Drug Development Explained
This whitepaper analyzes the FDA's draft guidance on AI in drug development, detailing its implications for industry practices and regulator…
High impact 5 min
🔒 ASHP Policy Positions 1982-2026
A comprehensive catalog of professional policy positions by ASHP, advocating for pharmacy practice and public health.
High impact 20 min
🔒 This whitepaper outlines the Medicare Advantage capitation rates and payment policies for 2027, emphasizing stakeholder feedback and risk ad…
High impact 20 min
🔒 Scientific Standards for 23andMe's Health and Trait Reports
This white paper outlines the scientific standards for 23andMe's genetic health and trait reports, emphasizing validity and evidence-based p…
High impact 4 min
Strengthening the FDA's Accelerated Approval Pathway: Progress and Unfinished Business
This whitepaper reviews the FDA's Accelerated Approval pathway, highlighting its evolution, challenges, and proposed reforms.
High impact 5 min
Frequently asked questions
What whitepapers does NovaPharmaNews publish?
Our research library curates FDA, EMA, and industry publisher PDFs — regulatory guidance, clinical analyses, manufacturing reports, and market intelligence. Each report includes an AI-summarized landing page with key takeaways and a gated PDF download.
How do I download a whitepaper?
Open any report page, scroll to the download form, and enter your work email. You receive instant PDF access and can opt in to weekly pharma intelligence updates. Downloads are free for healthcare professionals.
How do whitepapers connect to news and pipeline data?
Report pages link to related intelligence — company profiles, drug INN pages, clinical trials, pipeline programs, and topic hubs. Use the intelligence spokes on each page to explore the entity graph behind the research.
How often is the library updated?
New reports are ingested daily from leading publishers and regulatory sources. Featured picks highlight high-impact FDA, EMA, and industry research each week.